Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.

被引：0
|
作者：
Gide, Tuba Nur
Quek, Camelia
Madore, Jason
Menzies, Alexander M.
Dent, Rebecca
Carlino, Matteo S.
Guminski, Alex
Saw, Robyn
Thompson, John F.
Wilmott, James S.
Scolyer, Richard A.
Long, Georgina V.
机构：
[1] Univ Sydney, Melanoma Inst Australia, Cent Clin Sch, Fac Med, Sydney, NSW, Australia
[2] Melanoma Inst Australia, Sydney, NSW, Australia
[3] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, North Sydney, Australia
[4] Westmead Hosp, Melanoma Inst Australia, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia
[5] Blacktown Hosp, Sydney, NSW, Australia
[6] Univ Sydney, Royal North Shore Hosp, Melanoma Inst Australia, Sydney, NSW, Australia
[7] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[8] Univ Sydney, Melanoma Inst Australia, Royal Prince Alfred Hosp, Sydney, NSW, Australia
[9] Univ Sydney, Melanoma Inst Australia, Sydney Med Sch, Discipline Pathol, Sydney, NSW, Australia
[10] Univ Sydney, Melanoma Inst Australia, Mater Hosp, Royal North Shore Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 07期
关键词：
D O I：
10.1200/JCO.2017.35.7_suppl.51
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
51
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy
    Rogiers, Aljosja
    Dimitriou, Florentia
    Lobon, Irene
    Harvey, Catriona
    Vergara, Ismael A.
    da Silva, Ines Pires
    Lo, Serigne N.
    Scolyer, Richard A.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Long, Georgina V.
    EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [2] Predictive biomarkers for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
    Subrahmanyam, Priyanka
    Dong, Zhiwan
    Gusenleitner, Daniel
    Giobbie-Hurder, Anita
    Severgnini, Mariano
    Zhou, Jun
    Manos, Michael
    Maecker, Holden
    Hodi, F. Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [3] CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients
    Goltz, Diane
    Gevensleben, Heidrun
    Vogt, Timo J.
    Dietrich, Joern
    Golletz, Carsten
    Bootz, Friedrich
    Kristiansen, Glen
    Landsberg, Jennifer
    Dietrich, Dimo
    JCI INSIGHT, 2018, 3 (13):
  • [4] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
    Reddy, Swathi B.
    Possick, Jennifer D.
    Kluger, Harriet M.
    Galan, Anjela
    Han, Dale
    JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
  • [5] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
    Gauci, Marie-Lea
    Boudou, Philippe
    Baroudjian, Barouyr
    Vidal-Trecan, Tiphaine
    Da Meda, Laetitia
    Madelaine-Chambrin, Isabelle
    Basset-Seguin, Nicole
    Bagot, Martine
    Pages, Cecile
    Mourah, Samia
    Resche-Rigon, Matthieu
    Pinel, Sylvine
    Sassier, Marion
    Rouby, Franck
    Eftekhari, Pirayeh
    Lebbe, Celeste
    Gautier, Jean-Francois
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (08) : 1197 - 1208
  • [6] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
    Marie-Léa Gauci
    Philippe Boudou
    Barouyr Baroudjian
    Tiphaine Vidal-Trecan
    Laetitia Da Meda
    Isabelle Madelaine-Chambrin
    Nicole Basset-Seguin
    Martine Bagot
    Cécile Pages
    Samia Mourah
    Matthieu Resche-Rigon
    Sylvine Pinel
    Marion Sassier
    Franck Rouby
    Pirayeh Eftekhari
    Céleste Lebbé
    Jean-François Gautier
    Cancer Immunology, Immunotherapy, 2018, 67 : 1197 - 1208
  • [7] Melanoma tumor microbiome as a predictor of anti-PD-1 and anti-CTLA-4 immunotherapy response
    Uzelac, Matthew
    Li, Wei Tse
    Li, Yuxiang
    Ongkeko, Weg M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
    Willsmore, Zena N.
    Coumbe, Ben G. T.
    Crescioli, Silvia
    Reci, Sara
    Gupta, Ayushi
    Harris, Robert J.
    Chenoweth, Alicia
    Chauhan, Jitesh
    Bax, Heather J.
    McCraw, Alexa
    Cheung, Anthony
    Osborn, Gabriel
    Hoffmann, Ricarda M.
    Nakamura, Mano
    Laddach, Roman
    Geh, Jenny L. C.
    MacKenzie-Ross, Alastair
    Healy, Ciaran
    Tsoka, Sophia
    Spicer, James F.
    Josephs, Debra H.
    Papa, Sophie
    Lacy, Katie E.
    Karagiannis, Sophia N.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 (03) : 544 - 556
  • [9] Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
    Subrahmanyam, Priyanka B.
    Dong, Zhiwan
    Gusenleitner, Daniel
    Giobbie-Hurder, Anita
    Severgnini, Mariano
    Zhou, Jun
    Manos, Michael
    Eastman, Lauren M.
    Maecker, Holden T.
    Hodi, F. Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [10] Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
    Pollack, M. H.
    Betof, A.
    Dearden, H.
    Rapazzo, K.
    Valentine, I.
    Brohl, A. S.
    Ancell, K. K.
    Long, G. V.
    Menzies, A. M.
    Eroglu, Z.
    Johnson, D. B.
    Shoushtari, A. N.
    ANNALS OF ONCOLOGY, 2018, 29 (01) : 250 - 255
12345